epigallocatechin gallate has been researched along with Acute Confusional Senile Dementia in 87 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (9.20) | 29.6817 |
| 2010's | 51 (58.62) | 24.3611 |
| 2020's | 28 (32.18) | 2.80 |
| Authors | Studies |
|---|---|
| Carver, JA; Duggan, PJ; Ecroyd, H; Liu, Y; Meyer, AG; Tranberg, CE | 1 |
| Bulic, B; Mandelkow, E; Pickhardt, M | 1 |
| Boffi, A; D'Erme, M; Francioso, A; Giordano, C; Lori, C; Martire, S; Mosca, L; Punzi, P | 1 |
| Chen, GD; Feng, XL; Gao, H; Guo, LD; He, RR; Huang, Y; Li, XX; Yao, XS; Yu, Y; Zhao, Q; Zheng, YZ; Zhou, WX | 1 |
| Lei, Y; Liu, S; Ning, R; Wang, H; Wang, W; Zhang, H; Zhang, R; Zhao, W; Zhu, Y | 1 |
| Chen, J; Guo, YW; Ji, SS; Li, XW; Tao, LX; Wang, JR; Xiao, W; Zhang, HY | 1 |
| Alemi, M; Arsequell, G; Blasi, D; Cardoso, I; Cotrina, EY; Gimeno, A; Jiménez-Barbero, J; Llop, J; Quintana, J; Rivas, J; Santos, LM; Valencia, G | 1 |
| Camodeca, C; Ciccone, L; Fruchart-Gaillard, C; Nencetti, S; Nuti, E; Orlandini, E; Rossello, A; Shepard, W; Tonali, N | 1 |
| Huang, J; Huang, Y; Li, J; Li, W; Li, X; Sun, A; Wang, L; Wang, W; Xu, Y; Zhang, C; Zhang, H; Zhu, J | 1 |
| Blanch, EW; Dahdah, A; de Silva, NH; Hügel, HM; Maniam, S | 1 |
| Kshirsagar, S; Morton, H; Reddy, AP; Reddy, PH; Sawant, N | 1 |
| Jimenez-Del-Rio, M; Mendivil-Perez, M; Soto-Mercado, V; Velez-Pardo, C | 1 |
| Adinew, GM; Nahashon, S; Payne, A; Soliman, KFA; Taka, E | 1 |
| Alvir, RV; Hindle, A; Kshirsagar, S; Kumar, S; Pradeepkiran, JA; Ramasubramaniam, B; Reddy, AP; Reddy, PH; Vijayan, M | 1 |
| Abskharon, R; Boyer, DR; Cheng, X; DeTure, MA; Dickson, DW; Eisenberg, DS; Ge, P; Hu, CJ; Murray, KA; Pan, H; Sawaya, MR; Seidler, PM; Vinters, HV; Williams, CK | 1 |
| Fang, M; Guan, P; Hu, X; Su, K; Wang, X; Zhang, Q | 1 |
| Dong, X; Lin, X; Liu, W; Sun, Y | 1 |
| Arab, SS; Bozorgmehr, MR; Khoshbin, Z; Zahraee, H | 1 |
| Feng, S; Gui, X; Li, Y; Li, Z; Niu, Z; Reif, B; Shi, B | 1 |
| Chen, J; Gao, M; Han, Y; Huang, Y; Li, P; Ma, W; Qian, H; Su, Z; Wang, X; Ye, H; Yu, J | 1 |
| Andrikopoulos, N; Davis, TP; Ding, F; Ke, PC; Li, Y; Nandakumar, A; Quinn, JF; Saikia, N | 1 |
| Boeddrich, A; Brusendorf, L; Buntru, A; Czekelius, C; Diez, L; Helmecke, L; Kostova, S; Motzny, AY; Neuendorf, N; Reus, L; Schmieder, P; Schulz, A; Secker, C; Steinfort, R; Wanker, EE | 1 |
| Jha, HC; Mishra, A; Pandey, RK; Patra, P; Prashar, T; Rani, A; Saini, V | 1 |
| Ajumeera, R; Ayyalasomayajula, N; Challa, S; Chellu, CS | 1 |
| Choi, I; Danish Rizvi, SM; Farhana, A; Hussain, T; Nazam, N; Shaikh, S | 1 |
| Bao, J; Gui, YR; Liu, W; Long, GF; Shang, JT; Shu, XJ; Wu, MJ; Xiao, YF; Yang, YH; Zhou, HY | 1 |
| Mather, J; Okello, EJ | 1 |
| Luca, A; Paduraru, L; Stanciu, GD; Stefanescu, R; Tamba, BI | 1 |
| Li, H; Lv, L; Yang, F; Yuan, J | 1 |
| Menziani, MC; Pedone, A; Tavanti, F | 1 |
| Chen, JY; Lu, JH; OuYang, D; Zhang, S; Zhu, Q | 1 |
| Gruendler, R; Haslberger, AG; Hippe, B; Peterlin, B; Sendula Jengic, V | 1 |
| Abd El-Fattah, AI; Abu-Elfotuh, K; Ali, AA; Elariny, HA | 1 |
| Fan, J; Nan, S; Wang, P; Zhang, Y | 1 |
| Cordeiro, Y; Gonçalves, PB; Sodero, ACR | 1 |
| Guo, Q; Sheng, DY; Xu, ST; Yang, P; Zhang, QZ | 1 |
| Naina-Mohamed, I; Qodriyah, HMS; Syarifah-Noratiqah, SB; Zulfarina, MS | 1 |
| Chen, Y; Guo, Y; Nan, Y; Wang, S; Wang, X; Zhao, Y | 1 |
| Ngo, ST; Nguyen, MT; Tam, NM; Truong, DT | 1 |
| Hong, H; Li, Y; Su, B | 1 |
| Carpes, FP; Garcia, A; Martins, A; Mello-Carpes, PB; Schimidt, HL | 1 |
| Du, K; Liu, M; Wei, M; Wen, Q; Xiao, Q; Yang, B; Yao, W; Zhong, X | 1 |
| Dong, X; Jiang, Z; Liu, Y; Sun, Y; Yan, X; Zhang, L | 1 |
| Miyoshi, N; Nakamura, Y; Ohishi, T; Pervin, M; Tanabe, H; Unno, K | 1 |
| Koyama, N; Maeda, M; Mori, T; Segawa, T; Tan, J; Town, T | 1 |
| Busquets, O; Camins, A; Cano, A; Cominetti, MR; Di Luca, M; Endres, K; Ettcheto, M; Manzine, PR; Marcello, E; Olloquequi, J; Pelucchi, S | 1 |
| Auladell, C; Barenys, M; Barroso, E; Camins, A; Cano, A; Chang, JH; Espina, M; Ettcheto, M; Folch, J; García, ML; Kühne, BA; Souto, EB; Turowski, P | 1 |
| Almudimeegh, S; Berwick, DC; Cleverley, K; Fisher, EMC; Granno, S; Harvey, K; Heaton, G; Nagda, Z; Nixon-Abell, J; Plagnol, V; Rain, JC; Tosh, J; Tybulewicz, VLJ; Wiseman, FK; Zanda, M | 1 |
| Liu, MY; Wei, BB; Wei, MJ; Yao, WF; Zhong, X | 1 |
| Brender, JR; Choi, JS; DeToma, AS; Hyung, SJ; Kochi, A; Lee, S; Lim, MH; Ramamoorthy, A; Ruotolo, BT; Vivekanandan, S | 1 |
| Bokonjić, D; Igić, R; Jelenković, A; Jovanović, MD; Petronijević, N; Stevanović, I; Zivković, J | 1 |
| Derreumaux, P; Mu, Y; Zhang, J; Zhang, T | 1 |
| He, M; Liu, MY; Tang, QS; Wang, S; Wei, MJ; Yao, WF; Zhao, HS | 1 |
| Cao, YP; Han, K; Jia, N; Kong, JJ; Ren, GR; Sha, S; Zhang, XM | 1 |
| Cen, YZ; Chen, GD; Cui, JY; Gao, H; Guo, LD; Kong, MZ; Li, GQ; Li, XX; Wu, ZY; Zheng, QC; Zheng, YZ | 1 |
| Bernstein, SS; Bleiholder, C; Bowers, MT; Buratto, SK; Do, TD; Economou, NJ; Shea, JE; Wu, C | 1 |
| Ajit, D; Klakotskaia, D; Schachtman, TR; Serfozo, P; Simonyi, A; Sun, GY; Walker, JM; Weisman, GA; Wood, WG | 1 |
| Chang, X; Chen, Y; Cheng, S; Dun, W; Fang, S; Gu, X; He, W; Hou, X; Hu, Q; Liu, S; Mo, Y; Rong, C; Su, R; Wang, Q; Yang, C; Zhang, C; Zhang, L | 1 |
| de la Torre, R; Dierssen, M; Rodriguez-Morato, J; Xicota, L | 1 |
| Bongen, P; Brener, O; Demuth, HU; Dunkelmann, T; Funke, SA; Gremer, L; Hoyer, W; Janssen, A; Jürgens, D; Kadish, I; Kutzsche, J; Langen, KJ; Mirecka, EA; Nagel-Steger, L; Oesterhelt, F; Pietruszka, J; Rudolph, S; Tusche, M; van Groen, T; Willbold, D; Willuweit, A | 1 |
| Chan, S; Kantham, S; McGeary, RP; Palanivelu, MK; Pham, HL; Rao, VM; Ross, BP; Shaw, PN | 1 |
| Al Karaawi, MA; Al-Wabel, NA; Ali, B; Alzohairy, MA; Jamal, QM; Kamal, MA; Kesari, KK; Mushtaq, G; Shams, S; Siddiqui, MU | 1 |
| Khan, ZA; Mandal, AK; Singh, NA | 1 |
| Amit, T; Kalfon, L; Mandel, SA; Reznichenko, L; Weinreb, O; Youdim, MB | 1 |
| Amit, T; Mandel, SA; Reznichenko, L; Weinreb, O; Youdim, MB | 1 |
| Kim, J; Lee, HJ; Lee, KW | 1 |
| Bickford, PC; Fountain, M; Giunta, B; Shytle, RD; Smith, A; Tan, J | 1 |
| Giunta, B; Hou, H; Ruscin, A; Salemi, J; Shytle, RD; Tan, J; Zhu, Y | 1 |
| Jankun, J; Skrzypczak-Jankun, E | 1 |
| Fernandez, JW; Obregon, D; Rezai-Zadeh, K; Tan, J | 1 |
| Green, KN; Hendrix, C; LaFerla, FM; Parachikova, A | 1 |
| Bieschke, J; Fecht, HJ; Friedrich, RP; Hunstein, W; Mereles, D; Sommer, AP; Wanker, EE; Zhu, D | 1 |
| Bieschke, J; Dasari, M; Fink, U; Grelle, G; Lopez del Amo, JM; Reif, B; Wanker, EE | 1 |
| Sommer, AP | 1 |
| Bracale, R; Davinelli, S; Intrieri, M; Sapere, N; Scapagnini, G; Zella, D | 1 |
| Maag, JL; Musgrave, IF; Smid, SD | 1 |
| Kermode, AR; Zeng, Y; Zhao, T | 1 |
| Choi, DY; Han, SB; Hong, JT; Lee, YJ; Oh, KW; Yun, YP | 1 |
| Chan, CL; Ho, HM; Hu, P; Jiang, ZH; Liu, L; Wang, JR; Yau, LF; Zhang, H | 1 |
| Dunckley, T; Gokhale, V; Hulme, C; Medda, F; Smith, B | 1 |
| Cheng, XR; Hau, BY; Kerman, K; Kraatz, HB; Martic, S; Veloso, AJ | 1 |
| Amit, T; Mandel, S; Weinreb, O; Youdim, MB | 1 |
| Ehrhart, J; Hardy, J; Hou, H; Jeanniton, D; Morgan, D; Mori, T; Rezai-Zadeh, K; Shytle, D; Sun, N; Tan, J; Town, T; Townsend, K; Zeng, J | 1 |
| Arendash, GW; Bai, Y; Ehrhart, J; Hou, H; Mori, T; Obregon, DF; Rezai-Zadeh, K; Shytle, D; Sun, N; Tan, J; Town, T; Zeng, J | 1 |
| Amit, T; Avramovich-Tirosh, Y; Mandel, S; Youdim, MB | 1 |
| Joghataie, MT; Nobakht, M; Rasoolijazi, H; Roghani, M | 1 |
| Arendash, GW; Fernandez, F; Hou, H; Jensen, M; Rezai-Zadeh, K; Runfeldt, M; Shytle, RD; Tan, J | 1 |
22 review(s) available for epigallocatechin gallate and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Hydrogen Bonding; Models, Molecular; Protein Binding; Protein Conformation; Structure-Activity Relationship; tau Proteins | 2013 |
β-sheet interfering molecules acting against β-amyloid aggregation and fibrillogenesis.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Animals; Biological Products; Drug Discovery; Humans; Models, Molecular; Peptides; Polyphenols; Protein Aggregates; Protein Aggregation, Pathological; Protein Structure, Secondary | 2015 |
Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Catechin; Humans; Neuroinflammatory Diseases; Neuroprotection; Neuroprotective Agents | 2022 |
Epigallocatechin Gallate: A Multifaceted Molecule for Neurological Disorders and Neurotropic Viral Infections.
Topics: Alzheimer Disease; Epstein-Barr Virus Infections; Glycogen Synthase Kinase 3; Herpesvirus 4, Human; Humans; Nervous System Diseases; Phosphatidylinositol 3-Kinases; Zika Virus; Zika Virus Infection | 2023 |
Anti-Amyloid Aggregating Gold Nanoparticles: Can they Really be Translated from Bench to Bedside for Alzheimer's Disease Treatment?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Biomarkers; Blood-Brain Barrier; Brain; Catechin; Gene Expression Regulation; Gold; Humans; Metal Nanoparticles; Molecular Targeted Therapy; Neuroprotective Agents; Protein Aggregates; Resveratrol; Translational Research, Biomedical | 2020 |
Secondary Metabolites from Plants Possessing Inhibitory Properties against Beta-Amyloid Aggregation as Revealed by Thioflavin-T Assay and Correlations with Investigations on Transgenic Mouse Models of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzothiazoles; Biological Products; Catechin; Flavonoids; Fluorescent Dyes; Luteolin; Mice; Mice, Transgenic; Protein Aggregates; Silybin | 2020 |
The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer's disease animal model: A systematic review.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antioxidants; Blood-Brain Barrier; Catechin; Cognition; Disease Models, Animal; Humans; Neuroprotective Agents; Phosphorylation | 2020 |
Nutraceutical Approaches of Autophagy and Neuroinflammation in Alzheimer's Disease: A Systematic Review.
Topics: Alzheimer Disease; Animals; Autophagy; Catechin; Cellular Senescence; Dietary Supplements; Flavonols; Humans; Inflammation; Spermidine | 2020 |
Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Protein Precursor; Catechin; Drug Discovery; Humans; Molecular Targeted Therapy; Neurodegenerative Diseases; Parkinson Disease; Protein Aggregates; Protein Folding; Tea | 2021 |
Natural Polyphenols in the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Catechin; Curcumin; Disease Progression; Humans; Neuroprotective Agents; Oxidative Stress; Polyphenols; Resveratrol | 2018 |
Beneficial Effects of Green Tea Catechins on Neurodegenerative Diseases.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Camellia sinensis; Catechin; Cerebral Cortex; Humans; Molecular Docking Simulation; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Tea | 2018 |
ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker.
Topics: ADAM10 Protein; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Biomarkers; Catechin; Ginkgo biloba; Humans; Membrane Proteins; Neuroprotective Agents; Plant Extracts | 2019 |
Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease.
Topics: Alzheimer Disease; Animals; Catechin; Clinical Trials as Topic; Disease Models, Animal; Humans; Neuroprotective Agents; Oxidative Stress; Secondary Prevention; Treatment Outcome | 2017 |
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG).
Topics: Alzheimer Disease; Animals; Antioxidants; Catechin; Humans; Lipid Peroxidation; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Polyphenols; Reproducibility of Results; Signal Transduction; Tea | 2016 |
Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG).
Topics: Alzheimer Disease; Catechin; Flavonoids; Humans; Iron Chelating Agents; Neurodegenerative Diseases; Nootropic Agents; Phenols; Polyphenols; Signal Transduction; Tea | 2008 |
Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antioxidants; Brain; Catechin; Cells, Cultured; Humans; Hypoxia-Inducible Factor 1; Iron; Neuroprotective Agents; Parkinson Disease; Protein Kinase C | 2008 |
Naturally occurring phytochemicals for the prevention of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Catechin; Cognition Disorders; Curcumin; Dietary Supplements; Humans; Oxidative Stress; Phytotherapy; Plant Extracts; Resveratrol; Stilbenes | 2010 |
Pleiotropic protective effects of phytochemicals in Alzheimer's disease.
Topics: Alzheimer Disease; Catechin; Curcumin; Humans; Neuroprotective Agents; NF-E2-Related Factor 2; Polyphenols; Resveratrol; Stilbenes | 2012 |
Dietary polyphenol-derived protection against neurotoxic β-amyloid protein: from molecular to clinical.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Catechin; Cell Line; Curcumin; Diet; Humans; Models, Molecular; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Plants; Polyphenols; Resveratrol; Stilbenes; Tea | 2012 |
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Topics: Alzheimer Disease; Animals; Anthraquinones; Biomedical Research; Carbolines; Catechin; Chromosomes, Human, Pair 21; Coumarins; Down Syndrome; Drug Design; Dyrk Kinases; Humans; Mice; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; tau Proteins | 2012 |
Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases.
Topics: Alzheimer Disease; Animals; Antioxidants; Apoptosis; Catechin; Dietary Supplements; Disease Models, Animal; Flavonoids; Gene Expression Regulation; Humans; Iron Chelating Agents; Neuroprotective Agents; Parkinson Disease; Phenols; Polyphenols; Signal Transduction; Tea | 2004 |
Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Catechin; Cell Cycle; Humans; Hydroxyquinolines; Iron; Iron Chelating Agents; Neurodegenerative Diseases; Neuroprotective Agents; PC12 Cells; Piperazines; Rats | 2008 |
65 other study(ies) available for epigallocatechin gallate and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Caseins; Flavonoids; Humans; Methylation; Milk; Structure-Activity Relationship | 2010 |
Nodulisporiviridins A-H, Bioactive Viridins from Nodulisporium sp.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Androstenes; Animals; Bacteriocins; Catechin; China; Crystallography, X-Ray; Disease Models, Animal; Humans; Molecular Conformation; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Peptide Fragments; Xylariales | 2015 |
Natural β-Dihydroagarofuran-Type Sesquiterpenoids as Cognition-Enhancing and Neuroprotective Agents from Medicinal Plants of the Genus Celastrus.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Celastrus; Cell Survival; Cognition; Esters; Humans; Molecular Structure; Neuroprotective Agents; Nuclear Magnetic Resonance, Biomolecular; Peptide Fragments; Plants, Medicinal; Sesquiterpenes | 2015 |
Design, synthesis and biological evaluation of novel chiral oxazino-indoles as potential and selective neuroprotective agents against Aβ25-35-induced neuronal damage.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Indoles; Molecular Structure; Neurons; Neuroprotective Agents; Oxazines; Peptide Fragments; Structure-Activity Relationship | 2016 |
Insights on the Interaction between Transthyretin and Aβ in Solution. A Saturation Transfer Difference (STD) NMR Analysis of the Role of Iododiflunisal.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Crystallography, X-Ray; Diflunisal; Humans; Magnetic Resonance Spectroscopy; Molecular Docking Simulation; Prealbumin; Protein Interaction Maps | 2017 |
Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis.
Topics: Alzheimer Disease; Binding Sites; Crystallography, X-Ray; Humans; Models, Molecular; Molecular Conformation; Neuroprotective Agents; Prealbumin; Propionates; Protein Aggregates; Protein Binding; Structure-Activity Relationship | 2020 |
Discovery of novel dual RAGE/SERT inhibitors for the potential treatment of the comorbidity of Alzheimer's disease and depression.
Topics: Aged; Alzheimer Disease; Comorbidity; Depression; Drug Design; Humans; Prospective Studies; Receptor for Advanced Glycation End Products | 2022 |
Regioselective pyrrolizidine bis-spirooxindoles as efficient anti-amyloidogenic agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Cycloaddition Reaction; Humans | 2022 |
Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.
Topics: Alzheimer Disease; Animals; Catechin; Cell Line; Coumarins; DNA-Binding Proteins; High Mobility Group Proteins; Hippocampus; Mice; Mitochondria; Mitochondrial Dynamics; Mitophagy; Neurons; NF-E2-Related Factor 2; Nuclear Respiratory Factor 1; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphorylation; Synapses; Synaptophysin; tau Proteins | 2021 |
(-)-Epigallocatechin-3-Gallate Diminishes Intra-and Extracellular Amyloid-Induced Cytotoxic Effects on Cholinergic-like Neurons from Familial Alzheimer's Disease PSEN1 E280A.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Catechin; Cells, Cultured; Cholinergic Neurons; Female; Gene Regulatory Networks; Humans; Hydrogen Peroxide; Microscopy, Fluorescence; Models, Biological; Mutation; Presenilin-1; Protein Aggregates | 2021 |
A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Catechin; Coumarins; Humans; Mice; Mitochondrial Dynamics; RNA, Messenger | 2022 |
Structure-based discovery of small molecules that disaggregate Alzheimer's disease tissue derived tau fibrils in vitro.
Topics: Alzheimer Disease; Amyloid; Amyloidosis; Catechin; Cryoelectron Microscopy; Drug Evaluation, Preclinical; Humans; tau Proteins; Tea | 2022 |
Insights into Molecular Mechanisms of EGCG and Apigenin on Disrupting Amyloid-Beta Protofibrils Based on Molecular Dynamics Simulations.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apigenin; Humans; Molecular Dynamics Simulation; Peptide Fragments; Protein Binding | 2022 |
Epigallocatechin gallate-derived carbonized polymer dots: A multifunctional scavenger targeting Alzheimer's β-amyloid plaques.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Carbon; Catechin; Humans; Plaque, Amyloid | 2023 |
A comprehensive computer simulation insight into inhibitory mechanisms of EGCG and NQTrp ligands on amyloid-beta assemblies as the Alzheimer's disease insignia.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Humans; Ligands; Molecular Dynamics Simulation; Peptide Fragments | 2023 |
Liquid-liquid phase separation of amyloid-β oligomers modulates amyloid fibrils formation.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Humans; Phase Transition; Protein Aggregation, Pathological; Sodium Dodecyl Sulfate | 2023 |
(-)-Epigallocatechin-3-gallate, a Polyphenol from Green Tea, Regulates the Liquid-Liquid Phase Separation of Alzheimer's-Related Protein Tau.
Topics: Alzheimer Disease; Catechin; Humans; Polyphenols; tau Proteins; Tea | 2023 |
Zinc-Epigallocatechin-3-gallate Network-Coated Nanocomposites against the Pathogenesis of Amyloid-Beta.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Catechin; Gold; Humans; Metal Nanoparticles; Zinc | 2023 |
The polyphenol EGCG directly targets intracellular amyloid-β aggregates and promotes their lysosomal degradation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Catechin; Humans; Lysosomes | 2023 |
Mitigative effects of epigallocatechin gallate in terms of diminishing apoptosis and oxidative stress generated by the combination of lead and amyloid peptides in human neuronal cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Annexin A5; Apoptosis; bcl-2-Associated X Protein; Camellia sinensis; Caspase 3; Catechin; Cell Cycle; Cell Line, Tumor; Cell Survival; Humans; Lead; Neurons; Neuroprotective Agents; Oxidative Stress; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species | 2019 |
Epigallocatechin-3-gallate Alleviates Cognitive Deficits in APP/PS1 Mice.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Catechin; Cognitive Dysfunction; Cytokines; Disease Models, Animal; Gene Expression Regulation; Humans; Mice; Mice, Transgenic; Mutation; Neuroprotective Agents; Presenilin-1; Treatment Outcome | 2020 |
Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Anti-Inflammatory Agents; Antioxidants; Butyrylcholinesterase; Catechin; Cholinergic Neurons; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Eels; Horses; Humans; Phytotherapy; Tea | 2020 |
Brain-targeted co-delivery of β-amyloid converting enzyme 1 shRNA and epigallocatechin-3-gallate by multifunctional nanocarriers for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Blood-Brain Barrier; Brain; Catechin; Disease Models, Animal; Humans; Mice; Mice, Transgenic; RNA, Small Interfering | 2020 |
Insights into the Effect of Curcumin and (-)-Epigallocatechin-3-Gallate on the Aggregation of Aβ(1-40) Monomers by Means of Molecular Dynamics.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Brain; Catechin; Curcumin; Humans; Hydrophobic and Hydrophilic Interactions; Molecular Dynamics Simulation; Peptide Fragments; Plaque, Amyloid; Protein Aggregates | 2020 |
Natural antioxidants enhance the power of physical and mental activities versus risk factors inducing progression of Alzheimer's disease in rats.
Topics: Alzheimer Disease; Animals; Antioxidants; Ascorbic Acid; Catechin; Disease Models, Animal; Disease Progression; Male; Mental Health; Physical Conditioning, Animal; Rats; Rats, Sprague-Dawley; Risk Factors; Selenium; Vitamin E | 2021 |
Epigallocatechin-3-Gallate Provides Protection Against Alzheimer's Disease-Induced Learning and Memory Impairments in Rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Antioxidants; Aspartic Acid Endopeptidases; Catechin; Cognition Disorders; Dose-Response Relationship, Drug; Hippocampus; Male; Maze Learning; Memory Disorders; Neuroprotective Agents; Peptide Fragments; Rats; Rats, Sprague-Dawley; Spatial Memory; tau Proteins | 2021 |
[Constructing Brain Aβ-Targeting Nanoparticles Loaded with EGCG for Treating Alzheimer's Disease in Mice].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Catechin; Disease Models, Animal; Hippocampus; Mice; Mice, Inbred ICR; Nanoparticles; Oligopeptides | 2021 |
(-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Catechin; Disease Models, Animal; Disks Large Homolog 4 Protein; Frontal Lobe; Hippocampus; Maze Learning; Memory Disorders; Mice; Motor Activity; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Phosphorylation; Random Allocation; Spatial Memory; Synaptophysin; tau Proteins | 2017 |
EGCG inhibits the oligomerization of amyloid beta (16-22) hexamer: Theoretical studies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Catechin; Molecular Dynamics Simulation; Peptide Fragments; Protein Conformation, beta-Strand; Static Electricity | 2017 |
Identification of Circulating miR-125b as a Potential Biomarker of Alzheimer's Disease in APP/PS1 Transgenic Mouse.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Biomarkers; Catechin; Cell Line, Tumor; Cognition Disorders; Disease Models, Animal; Gene Expression Regulation; Humans; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; MicroRNAs; Mutation; Neuroblastoma; Presenilin-1; Protease Inhibitors; RNA, Messenger | 2017 |
Green tea supplementation produces better neuroprotective effects than red and black tea in Alzheimer-like rat model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Body Weight; Catechin; Disease Models, Animal; Hippocampus; Male; Memory; Neuroprotective Agents; Oxidative Stress; Rats; Rats, Wistar; Tea | 2017 |
Epigallocatechin Gallate Reduces Amyloid β-Induced Neurotoxicity via Inhibiting Endoplasmic Reticulum Stress-Mediated Apoptosis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Caspase 12; Caspase 3; Catechin; Cell Line, Tumor; Cell Survival; Cerebral Cortex; Dietary Supplements; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Humans; Mice, Transgenic; Microscopy, Electron, Transmission; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Random Allocation; Transcription Factor CHOP | 2018 |
Nanogels of dual inhibitor-modified hyaluronic acid function as a potent inhibitor of amyloid β-protein aggregation and cytotoxicity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Catechin; Cell Line; Cell Proliferation; Cell Survival; Humans; Hyaluronic Acid; Hydrogels; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Polyethylene Glycols; Protein Aggregates | 2018 |
Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Behavior, Animal; Catechin; Cognitive Dysfunction; Coumaric Acids; Disease Models, Animal; Drug Therapy, Combination; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Presenilin-1 | 2019 |
Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Ascorbic Acid; Brain; Catechin; Disease Models, Animal; Drug Carriers; Drug Liberation; Endothelial Cells; Male; Mice, Inbred C57BL; Mice, Transgenic; Nanoparticles; Polyethylene Glycols; Polylactic Acid-Polyglycolic Acid Copolymer; Rats | 2019 |
Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus.
Topics: Adaptor Proteins, Signal Transducing; Aged; Alzheimer Disease; Animals; Axin Protein; Catechin; Chromosomes, Human, Pair 21; Disease Models, Animal; Down Syndrome; Down-Regulation; Dyrk Kinases; Female; HEK293 Cells; HeLa Cells; Hippocampus; Humans; Male; Mice; Middle Aged; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; RNA-Seq; Wnt Signaling Pathway | 2019 |
Increased BBB permeability contributes to EGCG-caused cognitive function improvement in natural aging rats: pharmacokinetic and distribution analyses.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Catechin; Cerebral Cortex; Cognition; Hippocampus; Male; Maze Learning; Memory; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Rats, Sprague-Dawley | 2019 |
Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-associated amyloid-β species.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Camellia sinensis; Catechin; Copper; Humans; Metals; Models, Molecular; Neuroprotective Agents; Nuclear Magnetic Resonance, Biomolecular; Peptide Fragments; Plant Extracts; Protein Binding; Protein Conformation; Protein Multimerization; Tandem Mass Spectrometry; Zinc | 2013 |
Influence of the green tea leaf extract on neurotoxicity of aluminium chloride in rats.
Topics: Acetylcholinesterase; Aluminum Chloride; Aluminum Compounds; Alzheimer Disease; Animals; Avoidance Learning; Brain; CA1 Region, Hippocampal; Camellia sinensis; Catechin; Chlorides; Glutathione; Male; Neurotoxicity Syndromes; Oxidation-Reduction; Rats; Rats, Wistar; Superoxide Dismutase; Tea | 2014 |
Molecular mechanism of the inhibition of EGCG on the Alzheimer Aβ(1-42) dimer.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Catechin; Circular Dichroism; Dimerization; Humans; Molecular Dynamics Simulation; Molecular Structure; Peptide Fragments; Thermodynamics | 2013 |
[Research on EGCG improving the degenerative changes of the brain in AD model mice induced with chemical drugs].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Catechin; Disease Models, Animal; Female; Galactose; Gene Expression Regulation; Hippocampus; Mice; Neurons; Neuroprotective Agents; Phytotherapy; Tea | 2012 |
(-)-Epigallocatechin-3-gallate alleviates spatial memory impairment in APP/PS1 mice by restoring IRS-1 signaling defects in the hippocampus.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blotting, Western; Catechin; Disease Models, Animal; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hippocampus; Immunohistochemistry; Insulin Receptor Substrate Proteins; JNK Mitogen-Activated Protein Kinases; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peptide Fragments; Phosphorylation; Presenilin-1; Proto-Oncogene Proteins c-akt; Serine; Signal Transduction; Tumor Necrosis Factor-alpha | 2013 |
Nodulisporisteriods A and B, the first 3,4-seco-4-methyl-progesteroids from Nodulisporium sp.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Androstenes; Catechin; Crystallography, X-Ray; Drug Evaluation, Preclinical; Humans; Lactones; Models, Molecular; Molecular Conformation; Peptide Fragments; Propionates; Protein Multimerization; Secosteroids; Xylariales | 2013 |
Ion mobility spectrometry reveals the mechanism of amyloid formation of Aβ(25-35) and its modulation by inhibitors at the molecular level: epigallocatechin gallate and scyllo-inositol.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Catechin; Humans; Inositol; Mass Spectrometry; Models, Molecular; Peptide Fragments; Protein Multimerization; Protein Structure, Secondary | 2013 |
Beneficial effects of dietary EGCG and voluntary exercise on behavior in an Alzheimer's disease mouse model.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anxiety; Catechin; Cerebral Cortex; Disease Models, Animal; Drinking Water; Female; Hippocampus; Housing, Animal; Humans; Male; Maze Learning; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Nootropic Agents; Peptide Fragments | 2015 |
(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression.
Topics: Alzheimer Disease; Animals; Catechin; Cell Proliferation; Cells, Cultured; CHO Cells; Cognition Disorders; Cricetulus; Disease Models, Animal; Mice; Neprilysin; Stereoisomerism; Up-Regulation | 2015 |
QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Carrier Proteins; Catechin; Disease Models, Animal; Ferredoxin-NADP Reductase; Humans; Inositol; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Transgenic; Oligopeptides; Protein Aggregation, Pathological; Taurine | 2015 |
Metal chelation, radical scavenging and inhibition of Aβ₄₂ fibrillation by food constituents in relation to Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Catechin; Chelating Agents; Curcumin; Free Radical Scavengers; Gallic Acid; Humans; Metals; Peptide Fragments | 2016 |
In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment.
Topics: Acetylcholine; Acetylcholinesterase; Alzheimer Disease; Amino Acid Sequence; Butyrylcholinesterase; Catechin; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Nootropic Agents; Phytochemicals; Polyphenols; Protein Binding; Synaptic Transmission; Tea | 2016 |
Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Biological Availability; Catechin; Cell Line, Tumor; Enzyme Induction; Humans; Lipids; Male; Mice; Nanoparticles; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley | 2010 |
Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Animals; Biological Availability; Brain; Catechin; Cell Line, Tumor; Drug Synergism; Female; Fish Oils; Mice; Mice, Transgenic; Tea | 2010 |
Theaflavin digallate inactivates plasminogen activator inhibitor: could tea help in Alzheimer's disease and obesity?
Topics: Alzheimer Disease; Biflavonoids; Catechin; Electrophoresis, Polyacrylamide Gel; Gallic Acid; Humans; Indoleacetic Acids; Mutation; Obesity; Plasminogen Activator Inhibitor 1; Protein Binding; Tea; Thrombelastography; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 2010 |
EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP.
Topics: ADAM Proteins; ADAM10 Protein; Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Catechin; Cell Line; Disease Models, Animal; Estrogen Receptor alpha; Female; Furin; Humans; Membrane Proteins; Mice; Models, Biological; Neuroprotective Agents; Phosphatidylinositol 3-Kinases; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Signal Transduction | 2010 |
Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease.
Topics: Acetylcysteine; Alkaloids; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Ascorbic Acid; Benzodioxoles; Brain; Catechin; Cerebral Cortex; Cognition; Curcumin; Dietary Supplements; Folic Acid; Hippocampus; Humans; Immunoblotting; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Transgenic; Piperidines; Polyunsaturated Alkamides; Thioctic Acid; Vitamin B Complex; Vitamins | 2010 |
670 nm laser light and EGCG complementarily reduce amyloid-β aggregates in human neuroblastoma cells: basis for treatment of Alzheimer's disease?
Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid; Antineoplastic Agents; Brain Neoplasms; Catechin; Humans; Low-Level Light Therapy; Microscopy, Fluorescence; Neuroblastoma; Tumor Cells, Cultured; Ultrasonography | 2012 |
Structural properties of EGCG-induced, nontoxic Alzheimer's disease Aβ oligomers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Catechin; Humans; Magnetic Resonance Spectroscopy; Neuroprotective Agents; Protein Conformation; Protein Denaturation; Protein Multimerization | 2012 |
A novel approach for addressing Alzheimer's disease: the chemo-optical synergism.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Catechin; Humans; Laser Therapy; Neuroprotective Agents | 2012 |
A plant cell-based system that predicts aβ42 misfolding: potential as a drug discovery tool for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Catechin; Cell Engineering; Curcumin; Drug Evaluation, Preclinical; Gene Expression; Genes, Reporter; Green Fluorescent Proteins; Humans; Microscopy, Fluorescence; Models, Biological; Mutation; Nicotiana; Peptide Fragments; Phosphotransferases (Alcohol Group Acceptor); Plant Cells; Protein Binding; Protein Conformation; Protein Folding; Recombinant Fusion Proteins; Resveratrol; Stilbenes | 2012 |
Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Behavior, Animal; Catechin; Cells, Cultured; Cyclooxygenase 2; Cytokines; Disease Models, Animal; Inflammation; Lipopolysaccharides; Male; Memory Disorders; Mice; Mice, Inbred ICR; Neurons; Nitric Oxide Synthase Type II; Peptide Fragments; Rats | 2013 |
A cellular lipidomic study on the Aβ-induced neurotoxicity and neuroprotective effects of EGCG by using UPLC/MS-based glycerolipids profiling and multivariate analysis.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Arachidonic Acid; Catechin; Glycerides; Lipid Metabolism; Multivariate Analysis; Neurons; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Phosphatidylcholines; Phospholipases A2; Phospholipids; Principal Component Analysis; Rats | 2012 |
Surface plasmon resonance imaging of amyloid-β aggregation kinetics in the presence of epigallocatechin gallate and metals.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Catechin; Copper; Ferric Compounds; Humans; Ions; Kinetics; Metals; Microscopy, Electron, Transmission; Peptide Fragments; Surface Plasmon Resonance; Thiazoles; Zinc | 2013 |
Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloidosis; Animals; Catechin; Cells, Cultured; Female; Flavonoids; Mice; Mice, Transgenic; Tea | 2005 |
ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Catechin; Endopeptidases; Female; Male; Mice; Mice, Inbred C57BL; Protein Structure, Tertiary; RNA, Small Interfering; Tea | 2006 |
The beneficial effect of (-)-epigallocatechin-3-gallate in an experimental model of Alzheimer's disease in rat: a behavioral analysis.
Topics: Alzheimer Disease; Animals; Catechin; Disease Models, Animal; Male; Maze Learning; Psychomotor Performance; Rats; Rats, Wistar | 2007 |
Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Catechin; Cognition Disorders; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Maze Learning; Mice; Mice, Transgenic; Mutation; Neuroprotective Agents; Phosphorylation; tau Proteins | 2008 |